Cancer drug delivery often feels like a city bus system designed by chaos - the treatment arrives late, misses half the stops, and somehow still charges full fare. This new breast cancer study tried a different route: pair standard pre-surgery chemotherapy with anlotinib, a targeted drug that blocks blood-vessel growth signals, and see whether more tumors get flattened before the surgeon ever picks up a scalpel.
That matters because HR+/HER2- breast cancer - the most common breast cancer subtype - is a weirdly frustrating customer. It often responds well enough to long-term hormone therapy, but when doctors use neoadjuvant therapy - treatment given before surgery - it usually does not rack up the dramatic pathologic complete response rates seen in some HER2-positive or triple-negative cases. In plain English: these tumors can be stubborn. Not villain-monologue stubborn, but definitely "ignores repeated emails" stubborn.
The setup: chemo plus a blood-supply sabotage plan
In this prospective phase II study, Ding and colleagues tested anlotinib combined with chemotherapy in patients with HR+/HER2- breast cancer before surgery. Anlotinib is a multitarget tyrosine kinase inhibitor that blocks pathways involved in tumor blood vessel formation, including VEGFR, FGFR, PDGFR, and c-Kit. Tumors love building new blood vessels - they're basically tiny illegal real-estate developers. Shut down the roadwork, and in theory you make it harder for the cancer to thrive.
The logic here is pretty straightforward: chemotherapy attacks fast-dividing cancer cells, while anlotinib may make the tumor microenvironment less cozy by disrupting the blood supply and growth signaling. Together, the team hoped for a stronger preoperative response than chemo alone typically delivers in this subtype.
The study was single-arm and single-center, which means everyone got the experimental combination and there was no randomized control group inside the trial itself. The authors also included real-world validation, which is helpful, though not the same thing as a large randomized phase III showdown. Science is often less "mic drop" and more "interesting, please investigate further."
Why this is interesting in the least flashy subtype
HR+/HER2- disease does not usually headline the "look at this jaw-dropping pathologic complete response" stories. That's part of why this paper stands out. For high-risk or locally advanced cases, doctors want better pre-surgery options, especially when the usual neoadjuvant approach produces only modest pathologic responses.
And here's the trick: in this subtype, pathologic complete response is less common and sometimes less predictive than it is in other breast cancer groups. So improving response before surgery is useful, but it's not the whole story. Researchers also care about whether treatment can downstage tumors, improve surgical options, and eventually reduce recurrence risk.
That makes this paper less like a fireworks show and more like a surprisingly effective plumbing repair. Not glamorous. Extremely useful if it works.
What the study suggests
Based on the abstract, the combination showed promising efficacy and manageable safety in the neoadjuvant setting for HR+/HER2- breast cancer. That is encouraging because this group has had a relative shortage of exciting neoadjuvant wins compared with other breast cancer subtypes.
The broader idea fits with a growing oncology trend: combine therapies that attack cancer from different angles instead of asking one drug to do all the emotional labor. Anti-angiogenic strategies - cutting off a tumor's ability to build and maintain blood vessels - have had mixed results across breast cancer settings, but researchers keep revisiting them with better combinations and better patient selection. Fair enough. Cancer has had a long run of being annoyingly adaptable.
Still, let's keep our lab coats only partially unbuttoned. A single-arm phase II trial can tell you whether something looks promising, but it cannot prove superiority over standard therapy. Without randomization, it's harder to know how much credit belongs to the new regimen versus patient selection or other factors.
The real-world "if this holds up" part
If larger trials confirm these findings, this approach could matter in a few practical ways:
- Better tumor shrinkage before surgery, which may make operations easier or expand breast-conserving options
- Improved outcomes for high-risk HR+/HER2- patients, a group that often needs better neoadjuvant tools
- A new targeted combo strategy in a subtype where splashy pre-surgery responses are uncommon
That's not a cure-all. It's a possible upgrade. More bus lanes, fewer delays.
The catch, because there is always a catch
A few caveats matter here.
First, single-center studies can reflect local practice patterns that do not always generalize. Second, anti-angiogenic drugs can bring side effects such as hypertension and other toxicities, so "promising" only counts if patients can actually tolerate the regimen. Third, HR+/HER2- breast cancer is biologically diverse. One patient's tumor may behave like a sleepy bureaucracy; another's acts like it drank six espressos and found a loophole.
The next step is obvious: larger randomized trials that compare this regimen directly against current standards and identify which patients benefit most.
Bottom line
This study takes a smart swing at a familiar problem: HR+/HER2- breast cancers often underwhelm in the neoadjuvant setting, and doctors need better ways to soften them up before surgery. Pairing chemotherapy with anlotinib may be one of those ways.
Not a miracle. Not a mic-drop finale. But maybe - maybe - a better transit map for getting treatment where it needs to go.
References
-
Ding J, Meng H, Wang Y, et al. Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2- breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation. Signal Transduct Target Ther. 2026. doi:10.1038/s41392-026-02788-0
-
Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838-2848. doi:10.1158/1078-0432.CCR-19-3492
-
Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3
-
Harbeck N, Gnant M. Breast cancer. Lancet. 2024;403(10427):572-590. doi:10.1016/S0140-6736(23)02759-7
-
Turner NC, Kingston B, Kilburn LS, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2023;388(11):995-1008. doi:10.1056/NEJMoa2214134
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.